Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Completed · Phase 1
Conditions studied: Colorectal Cancer, Diarrhea, Neutropenia
In brief
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug, combination chemotherapy, may kill more tumor cells. Studying samples of blood in the laboratory from patients with cancer receiving fluorouracil in combination with oxaliplatin and leucovorin calcium may help doctors learn how fluorouracil works in the body and how patients will respond to treatment. PURPOSE: This phase I trial is studying biomarker-guided fluorouracil in treating patients with colorectal cancer receiving combination chemotherapy.
Key facts
- Study ID
- NCT01164215
- Run by
- UNC Lineberger Comprehensive Cancer Center
- People needed
- 76
- Starts
- 2010-02-01
- Expected to finish
- 2013-09-01
- Last updated by the study team
- 2015-10-09
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Care of Western North Carolina — Asheville, North Carolina, United States
- Moses Cone Regional Cancer Center at Wesley Long Community Hospital — Greensboro, North Carolina, United States
- Leo W. Jenkins Cancer Center at ECU Medical School — Greenville, North Carolina, United States
- Rex Cancer Center at Rex Hospital — Raleigh, North Carolina, United States
- Marion L. Shepard Cancer Center — Washington, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.